Table 2

 Clinical and angiographic characteristics

TrialMean age (years)Proportion with diabetesProportion with previous MIReference diameter (mm)Lesion length (mm)
RAVEL60.745/238 (19%)86/238 (36%)2.629.6
SIRIUS62279/1058 (26%)318/1058 (31%)2.814.4
E-SIRIUS62.381/351 (23%)147/349 (42%)2.5515
C-SIRIUS60.524/100 (24%)45/100 (45%)2.6313.5
FUTURE I/II63.517/107 (16%)17/107 (16%)2.9810.3
SES-SMART6263/257 (24.5%)75/257 (29%)2.211.85
SCANDSTENT62.722/322 (6.8%)64/322 (20%)2.918
DIABETES66.5100%74/160 (46%)2.3414.9
ENDEAVOR II62239/1197 (20%)491/1197 (41%)2.614.22
SIROLIMUS subgroup62770/3790 (20.3%)1317/3788 (35%)2.5816.50
SCORE62.253/260 (20%)105/260 (40%)311.87
TAXUS I64.911/59 (19%)18/59 (30.5%)2.9611.29
ASPECT6035/177 (20%)44/177 (42%)2.9210.87
TAXUS II60.158/536 (11%)160/536 (30%)2.7510.5
TAXUS IV62.5316/1314 (24%)397/1314 (30%)2.7513.4
ELUTES6030/192 (16%)66/192 (34%)2.9610.8
TAXUS V63357/1156 (30%)333/1156 (29%)2.6917
TAXUS VI62.689/446 (20%)NA2.7920.6
DELIVER62.3299/1041 (29%)275/1041 (26%)2.8111.36
PATENCYNA12/60 (20%)NA2.89NA
PACLITAXEL subgroup611260/5241 (24%)1398/4735 (29%)317